CSPC Pharmaceutical Group Limited has announced that its irinotecan hydrochloride liposome injection, marketed under the brand name Duoenyi, has received marketing approval from the National Medical Products Administration of China for a new indication. The newly approved use is for combination therapy with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) as a first-line treatment for patients with metastatic pancreatic cancer. This marks the product's second approved indication in China, following its initial approval in September 2023 for second-line treatment in metastatic pancreatic cancer. No other organizations were mentioned as recipients of this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251212-11954145), on December 12, 2025, and is solely responsible for the information contained therein.